STRATEGIC INITIATIVE Advancing SickKids Innovations Beyond Proof of Principle with the Technology Advancement Program IP&C’s goal is to support SickKids innovations from discovery to impact, ensuring that promising research advances beyond the lab to make a real difference for patients and communities. Expanding beyond the Proof of Principle (PoP) Grant Competition, the Technology Advancement Program (TAP) is designed to advance late-stage pre-clinical health care innovations with structured mentorship, project governance, strategic networking opportunities, and up to $350,000 in funding. Supported by the SickKids Commercialization Advisory Board (CAB), TAP helps further develop discoveries and refine their pathways toward [...]

STRATEGIC INITIATIVE IP&C Establishes Commercialization Advisory Board to Guide SickKids Innovations The Industry Partnerships & Commercialization (IP&C) Office at is excited to announce the launch of the Commercialization Advisory Board (CAB), a strategic group assembled to support the advancement of SickKids innovations from research through to commercialization. Members will provide guidance, mentorship, and advice on commercialization pathways, partnerships, and investment opportunities. By leveraging their collective experience, the CAB will help IP&C and SickKids researchers navigate challenges in translating discoveries into solutions that extend beyond our institution. A key role for the CAB will be advising on [...]

JOB OPPORTUNITY SickKids IP&C is Now Hiring: Business Development Associate Medical technology is advancing at an incredible pace, reshaping how we diagnose, treat, and care for patients. At SickKids IP&C, we are committed to accelerating this progress by supporting the development and commercialization of innovative medical devices, diagnostics, and other biomedical technologies. To strengthen these efforts, we are seeking a motivated Business Development Associate to help evaluate, protect, and advance promising technologies from discovery to market. Applications close October 2, 2025. Read the Full Job Description and Apply Here Position Description We are seeking [...]

IN THE PRESS SickKids Named World's Best Children's Hospital The Hospital for Sick Children (SickKids) has been named by Newsweek and Statista as the best children’s health-care centre in the world, topping the list of 250 children's hospitals globally. “This is an incredible honour and something that all of us, not just at SickKids but across Ontario and Canada, should be extremely proud of,” says Dr. Ronald Cohn, President and CEO of SickKids. “As we’ve celebrated our 150th anniversary this year, I’ve often remarked that the care, research and learning that happen at SickKids are [...]

AWARD ANNOUNCEMENT SickKids Scientist Receives $1M Transformative Research Award to Advance Huntington’s Disease Treatment SickKids IP&C is excited to congratulate Dr. Christopher Pearson, Senior Scientist in the Genetics & Genome Biology program at SickKids, on receiving the 2025 Transformative Research Award from the Hereditary Disease Foundation (HDF). This prestigious award includes $1 million in funding to support the continued development of a novel therapeutic strategy for Huntington’s disease (HD). A recognized leader in the study of repeat expansion disorders, Pearson was among the first to show that repeat expansion variations continue to grow over time in [...]

FUNDING OPPORTUNITY Now Accepting Applications for the 2025 Proof of Principle Grant Competition Are you a SickKids researcher developing a therapeutic, diagnostic, or medical device with potential for real-world impact? The SickKids Industry Partnerships & Commercialization (IP&C) office is now accepting applications for the annual Proof of Principle (PoP) Grant Competition. The PoP Grant provides up to $100,000 in project funding, along with commercialization support, to help researchers advance early-stage innovations toward commercial readiness. The program is designed to help bridge the gap between discovery and market by supporting activities such as prototype validation, regulatory [...]

FUNDING ANNOUNCEMENT SickKids Researcher Receives Commercialization Grant for Development of COPD Treatment Dr. Christine Bear, Senior Scientist and Co-Director of the Cystic Fibrosis Centre at The Hospital for Sick Children (SickKids) and Professor at The University of Toronto, has been awarded $325,125 to support the commercialization of a novel treatment for chronic obstructive pulmonary disease (COPD). The funding was issued as part of the Canadian Institutes of Health Research (CIHR) Project Grant Program and is aimed at advancing discoveries towards effective health products and services. COPD is a common respiratory condition that affects approximately 300 million [...]

FUNDING ANNOUNCEMENT Radiant Biotherapeutics Secures $35 Million to Advance Multabody™ Therapeutics Industry Partnerships & Commercialization (IP&C) is excited to share that Radiant Biotherapeutics has closed a $35 million USD series A financing co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures. Radiant Biotherapeutics is a pharmaceutical company built upon the cutting-edge Multabody technology that was researched and developed by Dr. Jean-Philippe Julien at The Hospital for Sick Children (SickKids) and Dr. Bebhinn Treanor at the University of Toronto. By leveraging avidity and multi-specificity, Multabodies offer the potential to deliver [...]